| 2024 | | Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy
Cancer communications (London, England), 44(1). : 173-177, 2024 | 김영롱, 정근옥, 허중연 |
| 2022 | | Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
Frontiers in immunology, 13. : 1034774-1034774, 2022 | 정근옥 |
| 2022 | | Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy
Molecular cancer, 21(1). : 102-102, 2022 | 김철호, 정근옥 |
| 2021 | | Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity
Frontiers in immunology, 11. : 593748-593748, 2021 | 박해심, 정근옥, 최영우 |
| 2021 | | Affinity maturation of a t‐cell receptor‐like antibody specific for a cytomegalovirus pp65‐derived peptide presented by hla‐a*02:01
International journal of molecular sciences, 22(5). : 2349-2349, 2021 | 정근옥 |
| 2020 | | A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
Cancer immunology research, 8(1). : 46-56, 2020 | 김철호, 이현우, 정근옥, 함석진 |
| 2019 | | Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity
Scientific reports, 9. : 7772-7772, 2019 | 김승현, 박해심, 정근옥 |
